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There is a long rocky road from treatment targets elucidated
in mechanistic studies to application in routine medical care.
The translation may fail at any stage. Electrical carotid sinus
stimulation showed promising efficacy in animals, including
in the study by Domingos-Souza et al. published in this issue
and in patients [1]. Nevertheless, the technology may be at
the verge of extinction.
The arterial baroreflex is a powerful mechanism maintaining
blood pressure in the face of psychological and physiolo-
gical challenges. Carotid and aortic stretch receptors sense
altered vascular distention as blood pressure changes.
The signal is conveyed through baroreflex afferent nerves
to the brainstem and integrated with input from other sour-
ces. Then, efferent cardiovascular sympathetic and para-
sympathetic traffic is adjusted to attenuate the blood pressure
change. The baroreflex is crucial for short-term blood
pressure control in humans. Damage to afferent portions of
the baroreflex produces baroreflex failure with neurogenic
hypertensive surges [2]. In contrast, efferent baroreflex
dysfunction causes autonomic failure with disabling ortho-
static hypotension [3]. The idea that baroreflex mechanisms
regulate blood pressure levels in the long term is more
controversial. Changes in baroreflex regulation have been
observed in patients with arterial hypertension [4], which
likely increases blood pressure variability, an emerging risk
factor heralding excess cardiovascular risk [5]. Physiological
studies suggesting that baroreflex mechanisms contribute to
long-term blood pressure control [6] provided the rationale
for electrical carotid sinus stimulation.
Domingos-Souza et al. [1] report findings of a study
testing blood pressure responses to electrical carotid sinus
stimulation in rats with experimental hypertension induced
through nitric oxide synthase inhibition with L-NAME.
A sham group received L-NAME and underwent surgery
but was not treated with electrical carotid sinus stimulation.
Following one-hour baseline recordings, carotid sinus sti-
mulation was begun using an intermittent stimulation mode.
After 48 h, the measurements were repeated for one hour.
The authors also computed heart rate and blood pressure
variability to assess autonomic cardiovascular control and
performed ex vivo tests of explanted mesenteric resistance
vessels.
L-NAME-induced substantial arterial hypertension was
substantially improved by electrical carotid sinus stimula-
tion. However, blood pressure remained within the hyper-
tensive range. The authors observed subtle changes in heart
rate and blood pressure variability, which might indicate a
shift in the balance between sympathetic and para-
sympathetic modulation towards parasympathetic activation.
Yet, the groups may have been too small to reach a more
definitive conclusion, and more detailed physiological and
biochemical profiling would be required to nail down the
mechanism. However, the authors showed that electrical
carotid sinus stimulation does not change ex vivo vascular
reactivity to the alpha-adrenoreceptor agonist phenylephrine.
Remarkably, carotid sinus stimulation selectively improved
endothelium-dependent acetylcholine-induced vasodilation
ex vivo while endothelial nitric oxide synthase protein
expression or phosphorylation did not change.
The study by Domingos-Souza et al. [1] extends previous
studies performed in animals [6] and in patients [7], which
showed reductions in blood pressure with electrical carotid
sinus stimulation. However, the study also highlights an
important issue limiting the utility of the approach in routine
clinical practice. Blood pressure reduction with carotid
sinus simulation is at least in part mediated through sym-
pathetic inhibition [8]. On average, sympathetic nervous
system activity is increased in patients with resistant arterial
hypertension [4], which is the group that is most likely to be
eligible for carotid sinus stimulation. However, the sym-
pathetic nervous system contributions to blood pressure are
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highly variable between patients [8, 9]. Domingos-Souza
et al. excluded animals not showing a blood pressure drop
of >20 mmHg during stimulation from further analysis.
Only one-third of patients with arterial hypertension who
underwent surgical sympathectomy decades ago showed
relevant chronic blood pressure improvements [10]. Thus,
interventions targeting the sympathetic nervous system will
not be equally effective in all patients. We have to find ways
of identifying patients likely to benefit from carotid sinus
stimulation before implantation.
Technological issues also limit the clinical utility of
electrical carotid sinus stimulation in treating resistant
arterial hypertension, namely, invasiveness, limited battery
life, difficulties in optimal electrode placement for target
engagement, and lack of feedback control. Baroreflex
stimulators with electrodes wrapped around baroreflex
afferent nerves were utilized decades ago, but their use was
discontinued [11]. The more recently introduced first-
generation electrical carotid sinus stimulator [Rheos™]
was equipped with bilateral bipolar electrodes that were
applied around the carotid sinus but is no longer available
[12]. The second-generation device [neo™] features a uni-
lateral and unipolar disk-shaped electrode. Design evolution
yielded significant reductions in invasiveness. Compared
with bilateral surgery, unilateral electrode placement less
commonly produces complications, such as lymph edema.
Battery life has also increased but is still unsatisfactory for
chronic treatment. Unfortunately, these improvements may
have sacrificed efficacy [13].
Perhaps the most important reason why electrical carotid
sinus stimulation may get lost in translation is the lack of
data from controlled clinical trials. The first-generation
device was tested in the pivotal randomized Rheos trial,
which randomized 265 patients with resistant hypertension
in a 2:1 fashion to device activation one month or to device
activation six months following device implantation [14].
While the prospectively defined efficacy endpoint in the
controlled phase of the trial, a ≥10 mm Hg systolic blood
pressure reduction, was not significant, blood pressure
was significantly reduced. The second-generation device
showed promising efficacy data in an uncontrolled
trial [15]. However, a multicenter randomized controlled
trial [ClinicalTrials.gov Identifier: NCT01679132] was
suspended due to a lack of funding.
Despite all these challenges, we will conclude on a positive
note. Research fostered by electrical carotid sinus stimulator
development has had a fundamental impact on our under-
standing of human baroreflex regulation. In fact, the idea that
baroreflex mechanisms do not fully reset and contribute to
long-term blood pressure control has now been proven in
animals and in human beings. Moreover, patients implanted
with such devices provide insight in human physiology that
could not be gained otherwise [16]. Finally, we have also
learned that such treatment can effectively lower blood
pressure in a subset of patients with difficult-to-control arterial
hypertension. Meanwhile, novel technologies using electrical
carotid sinus stimulation guided by blood pressure feedback
have been shown to ameliorate hypertension and blood
pressure variability in animals. Overall, there are good reasons
to continue research in this area [17].
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